Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Piotroski F-Score: 3
Altman Z-Score: -192.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROA % -367.25
FPMI's ROA % is ranked lower than
99.99% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. FPMI: -367.25 )
Ranked among companies with meaningful ROA % only.
FPMI' s ROA % Range Over the Past 10 Years
Min: -1659.13  Med: -309.83 Max: -100
Current: -367.25
-1659.13
-100
ROC (Joel Greenblatt) % -8361.70
FPMI's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. FPMI: -8361.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FPMI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -19913.04  Med: -4194.26 Max: -186.67
Current: -8361.7
-19913.04
-186.67
3-Year EBITDA Growth Rate -54.10
FPMI's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. FPMI: -54.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FPMI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -54.1  Med: 49.5 Max: 460.4
Current: -54.1
-54.1
460.4
3-Year EPS without NRI Growth Rate -35.60
FPMI's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. FPMI: -35.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FPMI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.6 Max: 100
Current: -35.6
0
100
GuruFocus has detected 4 Warning Signs with FluoroPharma Medical Inc $FPMI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FPMI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with FPMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ENTB, OTCPK:PTEO, OTCPK:BPSR, OTCPK:ARNI, OTCPK:PRTT, OTCPK:LCAR, OTCPK:GOVX, OTCPK:TLOG, OTCPK:ERGO, OTCPK:CBBT, OTCPK:CAPS, OTCPK:NSPX, OTCPK:CRXM, OTCPK:CTTC, OTCPK:GLAG, OTCPK:NTRR, OTCPK:HDVY, OTCPK:OPLI, OTCPK:ICOTF, OTCPK:BTHE » details
Headquarter Location:USA
FluoroPharma Medical Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology.

FluoroPharma Medical Inc., is a molecular imaging company. It is engaged in the discovery, development and commercialization of proprietary products for the positron emission tomography (PET) market.

Top Ranked Articles about FluoroPharma Medical Inc

FluoroPharma Medical Announces Details for Investor Call on June 22, 2016
MONTCLAIR, NJ--(Marketwired - June 17, 2016) - FluoroPharma Medical, Inc. (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:30 p.m. EDT on Wednesday, June 22, 2016. The objectives of the call are to provide updates on recent company news and address questions from investors. Questions may be submitted prior to the call by posting to [email protected]. Participants who would like to ask questions during the question and answer session must participate by telephone. Participants are encouraged to dial-in fifteen minutes before the conference call begins. Investors and the public are invited to access the live audio cast:Event: FluoroPharma Medical, Inc. 2Q Investor CallDate and Time: Wednesday, June 22nd 4:30 PM EDTLive participant dial-in (Toll-free US and Canada): 877-407-8129
Live participant dial-in (International): 201-493-6710An audio replay link will be available after the completion of the call on the Investor Relations section of the Company's website: http://www.fluoropharma.com/About FluoroPharma MedicalFluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes. FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.comForward-Looking StatementsExcept for historical information contained herein, this release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in FluoroPharma's business. Examples of forward-looking statements include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, the likelihood or success of reaching a definitive agreement on any proposed transaction or letter of intent, the likelihood of success of a transaction once it occurs, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and FluoroPharma undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Media Contact:

Carol Perlman
FluoroPharma Medical, Inc.
[email protected]
Phone: (917) 592-9260
[email protected]



Read more...
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals
MONTCLAIR, NJ--(Marketwired - June 09, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has entered into a nonbinding letter of intent with Ground Fluor Pharmaceuticals, Inc. (GFP) to acquire GFP.The transaction is conditioned on the close of sufficient financing to fund the operations of the combined company, and due diligence review. FPMI intends to execute the transaction with a subsidiary of FPMI acquiring all shares of closely held GFP by payment with restricted stock, not to exceed a majority of FPMI's outstanding shares. "The addition of the GFP's intellectual property portfolio and product candidates compliments the late stage PET imaging assets we currently have in development. GFP's unique platform for producing high value F-18 PET agents enables the preparation of important, previously difficult to prepare agents at a scale required for widespread clinical use. For example, the GFP chemistry can enhance our ability to prepare our current agents on a commercial scale," said Thomas Tulip, Ph.D., FPMI's President and CEO. "GFP also provides late stage opportunities for additional product approvals and future revenue. FPMI believes that GFP's technology and product candidates can have significant value for patients, healthcare providers and for the Company's shareholders."Dr. Tulip would continue in the role of President and CEO of the combined company. Allan Green, MD, PhD, and CEO of GFP added, "The combination of Ground Fluor's products and technology with FluoroPharma's portfolio and management provides the opportunity to advance exciting new approaches to help patients with heart disease, cancer and degenerative neurological conditions. We're delighted by the prospect of this exciting combination of valuable Molecular Imaging assets." Additionally, FPMI is planning an investor call on Tuesday, June 21st. Details will be made available in the near future.Additional InformationThe proposed transaction may be subject to additional approvals depending on the transaction structure contained in any definitive agreement that may be entered into. We cannot provide any assurance that the required approvals will be granted, and in the event they are not, we will not be able to proceed with the transaction.Any consummation of the proposed transaction will need to be performed in compliance with applicable securities laws and regulations, and may require the filing of comprehensive disclosure documents.About FluoroPharma MedicalFluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston. The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.com.About Ground Fluor Pharmaceuticals, Inc.Ground Fluor Pharmaceuticals, Inc. (GFP) is a company based in Lincoln, NE and Cambridge, MA that has developed new chemistry technology which transforms complicated and costly fluorine syntheses into simpler, more efficient processes. Using technology developed at the University of Nebraska and the Massachusetts General Hospital and funded by the National Science Foundation and Cedarville Investments, Ltd., GFP has developed and patented processes and intermediate chemicals for the efficient, cost-effective production of PET imaging agents.This press release consists of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. In particular, there is no assurance that the parties will reach a definitive agreement for the proposed transaction or that the transaction will be completed. Additionally, no assurance can be provided that the terms of any transaction will be similar to those contemplated by the nonbinding Letter of Intent. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties, and actual results could differ materially from those indicated by such forward-looking statements. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events, or otherwise.
Media Contact:

Carol Perlman
FluoroPharma Medical, Inc.
[email protected]
Phone: (917) 592-9260
[email protected]



Read more...
FluoroPharma Enters Development and Commercialization Agreement for China and Canada
MONTCLAIR, NJ--(Marketwired - June 06, 2016) - FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma's proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.In exchange, FluoroPharma expects to earn significant revenue based on unit sales to Sinotau and royalties based on Sinotau's sales of both imaging agents. In addition to a $550,000 upfront payment to FluoroPharma, up to $1.4 million in development milestone payments have also been established. CardioPET, the company's lead imaging asset, is a fatty acid analog that targets the heart's primary energy source, and promises to provide unique insight into cardiac physiology versus older technologies like SPECT. CardioPET has completed enrollment in a Phase II study in Europe, and will advance to additional clinical studies in the US. BFPET, entering Phase II studies in the US, is a marker of mitochondrial membrane integrity and can be used to evaluate myocardial perfusion with all the potential benefits of Fluorine-18 PET imaging, such as higher image resolution fewer image artifacts. "We are pleased to have reached agreement with such a well-established partner as Sinotau," said Thomas Tulip, Ph.D., President and Chief Executive Officer of FluoroPharma. "As cardiovascular disease prevalence continues to rise in China, Canada, and around the world, we believe these assets will play a major role in how heart disease is diagnosed and managed appropriately." According to the World Health Organization, the death rate from cardiovascular disease in China is nearly double that of cancer, and across Asia it now exceeds the mortality rates for CVD in other developed countries. "We are pleased to have a partnership that combines FluoroPharma's radiopharmaceutical assets with our extensive development, regulatory, sales, and marketing capabilities," commented Xu Xinsheng, Sinotau President and CEO. "Our goal is to offer novel radiopharmaceutical approaches to improve care and patient outcomes with the growing cardiovascular disease problem in China. Ultimately, we are focused on having an impact on the growing concern of cost implications and quality of care in such a large population." As part of the agreement, Sinotau is responsible for the costs and conduct of clinical studies and regulatory applications to obtain approval by the China Food and Drug Administration (CFDA) and Health Canada. Upon approval, Sinotau will be primarily responsible for all CardioPET and BFPET sales, marketing, market access and medical affairs activities in China and Canada. FluoroPharma and Sinotau will jointly support certain pre-market planning activities with a joint commitment on clinical and market development programs pending CFDA and Health Canada approvals. "This is the first of many important partnerships which we anticipate during the course of our clinical development," added Dr. Tulip. "The ongoing advance of CVD and the need for better and more efficient solutions in healthcare worldwide give us increased confidence in the inherent value of our portfolio, and our ability to deliver shareholder value as well."About FluoroPharma MedicalFluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.com.About Sinotau Pharmaceutical Group Sinotau Pharmaceutical Group is a pharmaceutical company focused on the registration and commercialization of imported and domestic generic formulations in the Mainland China market. Sinotau commenced operations in 2002 with the purpose of providing access to quality medicines to patients across China; it has experienced strong growth throughout its lifespan with coverage of all of the Mainland Chinese market. Sinotau's strategic focus lies in developing a product portfolio centered on Oncology, Antiretroviral, Central Nervous System and Cardiovascular System therapies in partnership with leading multinational pharmaceutical firms. The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance and anticipated revenue, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward- looking statements.
Media Contact:

Carol Perlman
FluoroPharma Medical, Inc.
[email protected]
Phone: (917) 592-9260
[email protected]



Read more...

Ratios

vs
industry
vs
history
EV-to-EBIT -9.26
FPMI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. FPMI: -9.26 )
Ranked among companies with meaningful EV-to-EBIT only.
FPMI' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.89  Med: 0 Max: 0
Current: -9.26
-10.89
0
EV-to-EBITDA -9.82
FPMI's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. FPMI: -9.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
FPMI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.53  Med: 0 Max: 0
Current: -9.82
-11.53
0

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.90
FPMI's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. FPMI: -9.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FPMI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.7  Med: -10.6 Max: -1.4
Current: -9.9
-32.7
-1.4

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -10.79
FPMI's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. FPMI: -10.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FPMI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -20.63  Med: 0 Max: 0
Current: -10.79
-20.63
0

More Statistics

EPS (TTM) $ -0.09
Beta1.04
Short Percentage of Float0.00%
52-Week Range $0.03 - 0.29
Shares Outstanding (Mil)34.26
» More Articles for FPMI

Headlines

Articles On GuruFocus.com
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016 Jun 17 2016 
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals Jun 09 2016 
FluoroPharma Enters Development and Commercialization Agreement for China and Canada Jun 06 2016 
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific May 25 2016 

More From Other Websites
FluoroPharma and Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial Oct 18 2016
FluoroPharma Announces CardioPET Phase II Results at the 21st American Society of Nuclear Cardiology... Sep 26 2016
FluoroPharma Medical Announces Details for Investor Call on June 22, 2016 Jun 17 2016
FluoroPharma Announces a Letter of Intent to Acquire Ground Fluor Pharmaceuticals Jun 09 2016
FluoroPharma Enters Development and Commercialization Agreement for China and Canada Jun 06 2016
FluoroPharma Medical Announces Acceptance of CardioPET Data for Presentation at the 21st Scientific... May 25 2016
FluoroPharma Medical Announces Details for Investor Call on January 6th Jan 05 2016
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer Dec 29 2015
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the... Oct 23 2015
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc. Oct 06 2015
FluoroPharma Medical, Inc. Earnings Q2, 2015 Sep 01 2015
FPMI: 2014 Results, Maintaining Buy Recommendation Apr 01 2015
FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh... Jan 16 2015
FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of... Dec 04 2014
FPMI: CardioPET Data A Catalyst to Share Price Appreciation Nov 20 2014
Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study... Nov 03 2014
FPMI: Data Continues To Support Utility of CardioPET Oct 20 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Oct 20 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Sep 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)